Summary
Ductal carcinoma in situ (DCIS) is a heterogeneous disease in both its biology and clinical course. In the past, recurrence rates after breast-conserving surgery have been as high as 30% after 10 years. The introduction of mammography screening and advances in imaging have led to an increase in the detection of DCIS. The focus of this review is on the role of radiotherapy in the multidisciplinary treatment, including current developments in hypofractionation and boost delivery, and attempts to define low-risk subsets of DCIS for which the need for adjuvant radiation is repeatedly questioned.
References
1.
Lynge E, Ponti A, James T, et al.: Variation in detection of ductal carcinoma in situ during screening mammography: A survey within the international cancer screening network. Eur J Cancer 2014;50:185-192.
2.
Souchon R, Sautter-Bihl ML, Sedlmayer F, et al.: DEGRO practical guidelines: Radiotherapy of breast cancer II: Radiotherapy of non-invasive neoplasia of the breast. Strahlenther Onkol 2014;190:8-16.
3.
Early Breast Cancer Trialists' Collaborative Group, Correa C, McGale P, et al.: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010;2010:162-177.
4.
Warnberg F, Garmo H, Emdin S, et al.: Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol 2014;32:3613-3618.
5.
Bekelman JE, Sylwestrzak G, Barron J, et al.: Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013. JAMA 2014;312:2542-2550.
6.
Bartelink H, Maingon P, Poortmans P, et al.: Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015;16:47-56.
7.
Silverstein MJ, Poller DN, Waisman JR, et al.: Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995;345:1154-1157.
8.
Silverstein MJ, Lagios MD, Craig PH, et al.: A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-2274.
9.
Silverstein MJ: The University of Southern California/Van Nuys Prognostic Index for ductal carcinoma in situ of the breast. Am J Surg 2003;186:337-343.
10.
Boland GP, Chan KC, Knox WF, et al.: Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 2003;90:426-432.
11.
MacAusland SG, Hepel JT, Chong FK, et al.: An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 2007;110:2648-2653.
12.
Altintas S, Toussaint J, Durbecq V, et al.: Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): New tools for ductal carcinoma in situ (DCIS). Breast J 2011;17:343-351.
13.
Kerlikowske K, Molinaro AM, Gauthier ML, et al.: Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-637.
14.
Solin LJ, Gray R, Baehner FL, et al.: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013;105:701-710.
15.
Hughes LL, Wang M, Page DL, et al.: Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-5324.
16.
Wong JS, Kaelin CM, Troyan SL, et al.: Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006;24:1031-1036.
17.
Wong JS, Chen YH, Gadd MA, et al.: Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat 2014;143:343-350.
18.
Williams KE, Barnes NL, Cramer A, et al.: Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol 2015;26:1019-1025.
19.
Curigliano G, Disalvatore D, Esposito A, et al.: Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. Ann Oncol 2015;26:682—693.
20.
McCormick B, Winter K, Hudis C, et al.: RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 2015;33:709-715.
21.
Sedlmayer F, Sautter-Bihl ML, Budach W, et al.: DEGRO practical guidelines: Radiotherapy of breast cancer I: Radiotherapy following breast conserving therapy for invasive breast cancer. Strahlenther Onkol 2013;189:825-833.
22.
Duma MN, Molls M, Trott KR: From heart to heart for breast cancer patients - cardiovascular toxicities in breast cancer radiotherapy. Strahlenther Onkol 2014;190:5-7.
23.
Boekel NB, Schaapveld M, Gietema JA, et al.: Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2014;106,pii:dju 156.
24.
Julian TB, Mamounas EP, Costantino JP, Wolmark N: Is boost therapy necessary in the treatment of DCIS? J Clin Oncol 2008;26:537.
25.
Omlin A, Amichetti M, Azria D, et al.: Boost radiotherapy in young women with ductal carcinoma in situ: A multicentre, retrospective study of the rare cancer network. Lancet Oncol 2006;7:652-656.
26.
Wong P, Lambert C, Agnihotram RV, et al.: Ductal carcinoma in situ-the influence of the radiotherapy boost on local control. Int J Radiat Oncol Biol Phys 2012;82:e153-158.
27.
Meattini I, Livi L, Franceschini D, et al.: Role of radiotherapy boost in women with ductal carcinoma in situ: A single-center experience in a series of 389 patients. Eur J Surg Oncol 2013;39:613-618.
28.
Monteau A, Sigal-Zafrani B, Kirova YM, et al.: Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: Treatment with reexcision or radiotherapy with increased dosage. Int J Radiat Oncol Biol Phys 2009;75:1021-1028.
29.
Nilsson C, Valachis A: The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: A meta-analysis of observational studies. Radiother Oncol 2015;114:50-55.
30.
Haviland JS, Owen JR, Dewar JA, et al.: The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:1086-1094.
31.
Whelan TJ, Pignol JP, Levine MN, et al.: Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513-520.
32.
Ciervide R, Dhage S, Guth A, et al.: Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:e159-164.
33.
Dellas K, Vonthein R, Zimmer J, et al.: Hypofractionation with simultaneous integrated boost for early breast cancer: Results of the German multicenter phase II trial (ARO-2010-01). Strahlenther Onkol 2014;190:646-653.
34.
Hathout L, Hijal T, Theberge V, et al.: Hypofractionated radiation therapy for breast ductal carcinoma in situ. Int J Radiat Oncol Biol Phys 2013;87:1058-1063.
35.
Lalani N, Paszat L, Sutradhar R, et al.: Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 2014;90:1017-1024.
36.
Donker M, Litiere S, Werutsky G, et al.: Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013;31:4054-4059.
37.
Recht A: Are the randomized trials of radiation therapy for ductal carcinoma in situ still relevant? J Clin Oncol 2014;32:3588-3590.
38.
Smith BD: When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ. J Clin Oncol 2015;33:686-691.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
